HL Financial Services LLC raised its position in Allergan plc (NYSE:AGN) by 3.0% in the 3rd quarter, HoldingsChannel.com reports. The firm owned 619,581 shares of the company’s stock after buying an additional 18,125 shares during the quarter. Allergan accounts for 1.8% of HL Financial Services LLC’s holdings, making the stock its 17th largest position. HL Financial Services LLC’s holdings in Allergan were worth $118,018,000 as of its most recent SEC filing.
Other large investors have also recently made changes to their positions in the company. Flagship Harbor Advisors LLC bought a new position in Allergan in the 2nd quarter valued at $129,000. Gradient Investments LLC boosted its holdings in Allergan by 747.5% in the 3rd quarter. Gradient Investments LLC now owns 678 shares of the company’s stock valued at $129,000 after purchasing an additional 598 shares during the period. Kaizen Advisory LLC boosted its holdings in Allergan by 156.2% in the 2nd quarter. Kaizen Advisory LLC now owns 830 shares of the company’s stock valued at $138,000 after purchasing an additional 506 shares during the period. Migdal Insurance & Financial Holdings Ltd. boosted its holdings in Allergan by 3,193.3% in the 2nd quarter. Migdal Insurance & Financial Holdings Ltd. now owns 988 shares of the company’s stock valued at $165,000 after purchasing an additional 958 shares during the period. Finally, Aries Wealth Management bought a new position in Allergan in the 2nd quarter valued at $202,000. 77.55% of the stock is owned by hedge funds and other institutional investors.
In other Allergan news, Director Joseph H. Boccuzi bought 900 shares of the firm’s stock in a transaction that occurred on Thursday, August 30th. The shares were bought at an average price of $190.59 per share, for a total transaction of $171,531.00. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Christopher J. Coughlin bought 10,000 shares of the firm’s stock in a transaction that occurred on Thursday, September 6th. The stock was acquired at an average price of $190.64 per share, for a total transaction of $1,906,400.00. The disclosure for this purchase can be found here. 0.37% of the stock is owned by company insiders.
AGN has been the subject of several analyst reports. Wells Fargo & Co set a $240.00 price target on shares of Allergan and gave the company a “buy” rating in a report on Thursday, July 19th. Zacks Investment Research raised shares of Allergan from a “hold” rating to a “buy” rating and set a $197.00 price objective for the company in a report on Tuesday, July 17th. Credit Suisse Group set a $213.00 price objective on shares of Allergan and gave the stock a “buy” rating in a report on Friday, July 13th. Mizuho raised shares of Allergan from a “neutral” rating to a “buy” rating in a report on Friday, August 3rd. Finally, Deutsche Bank set a $210.00 price objective on shares of Allergan and gave the stock a “buy” rating in a report on Wednesday, September 12th. Two investment analysts have rated the stock with a sell rating, five have issued a hold rating and eighteen have given a buy rating to the stock. Allergan currently has an average rating of “Buy” and a consensus target price of $210.18.
Shares of NYSE:AGN opened at $163.05 on Monday. The firm has a market capitalization of $54.99 billion, a P/E ratio of 9.97, a price-to-earnings-growth ratio of 1.29 and a beta of 1.31. Allergan plc has a 52 week low of $142.81 and a 52 week high of $197.00. The company has a debt-to-equity ratio of 0.32, a quick ratio of 0.78 and a current ratio of 0.92.
Allergan (NYSE:AGN) last issued its earnings results on Tuesday, October 30th. The company reported $4.25 EPS for the quarter, topping analysts’ consensus estimates of $4.04 by $0.21. The company had revenue of $3.91 billion for the quarter, compared to analysts’ expectations of $3.89 billion. Allergan had a net margin of 14.50% and a return on equity of 8.44%. The firm’s revenue was down 3.0% compared to the same quarter last year. During the same quarter last year, the company earned $4.15 EPS. As a group, equities analysts forecast that Allergan plc will post 16.43 earnings per share for the current fiscal year.
The firm also recently announced a quarterly dividend, which will be paid on Friday, December 14th. Investors of record on Tuesday, November 13th will be given a $0.72 dividend. This represents a $2.88 dividend on an annualized basis and a yield of 1.77%. The ex-dividend date is Friday, November 9th. Allergan’s payout ratio is presently 17.61%.
Allergan plc, a pharmaceutical company, develops, manufactures, and commercializes branded pharmaceutical, device, biologic, surgical, and regenerative medicine products worldwide. It operates through US Specialized Therapeutics, US General Medicine, and International segments. The company offers a portfolio of products for the central nervous system, eye care, medical aesthetics and dermatology, gastroenterology, women's health, urology, and anti-infective therapeutic categories.
Further Reading: How Do You Calculate Return on Investment (ROI)?
Want to see what other hedge funds are holding AGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Allergan plc (NYSE:AGN).
Receive News & Ratings for Allergan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan and related companies with MarketBeat.com's FREE daily email newsletter.